Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Expansion of primitive, CD34+ cord blood cells with histone deacetylase (HDAC) inhibitors

Mouse and ex vivo studies suggest HDAC inhibitors could be used to expand functional cord blood stem cells for transplant. In serum-free cultures of CD34+ hematopoietic progenitor cells, the HDAC inhibitor valproic acid (VPA) increased CD34+ cell numbers by 4.2-fold and multipotent CD34+ and thymus cell antigen 1q (Thy1; CD90)+ cell numbers by 144-fold compared with medium alone. In immunodeficient mice, transplanted human CD34+ cells treated with VPA and primed with cytokines showed greater engraftment than cells that were only primed with cytokines. Next steps could include assessing the efficacy of the method for replenishing all hematopoietic cell lineages in mice.

SciBX 7(22); doi:10.1038/scibx.2014.660
Published online June 5, 2014

Patent and licensing status unavailable

Chaurasia, P. et al. J. Clin. Invest.; published online April 24, 2014;
doi:10.1172/JCI70313
Contact: Ronald Hoffman, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, N.Y.
e-mail:

ronald.hoffman@mssm.edu
Contact: Pratima Chaurasia, same affiliation as above
e-mail:

pratima.chaurasia@mssm.edu